🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 Hot off the press! 🚨 The ESMO - Eur. Oncology Precision Oncology Working Group, led by the amazing Ben Westphalen G Curigliano MD PhD has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology

La medicina no es sólo ciencia, sino también un acto profundo de humanidad. El médico no es solo un técnico: es un servidor de la vida, llamado a sanar con conocimiento, pero también con compasión y ternura. Estados llamados a unir ciencia y conciencia, técnica y corazón.

Some moments from #AACR25 meeting with Bill Dahut, MD G Curigliano MD PhD Eli Van Allen Ziad Bakouny, MD, MSc Charles Swanton and co-chairs MVH Lab Lillian Siu cc: AACR

It was a great honour to be invited to the AACR President's Dinner by the AACR president Dr. Patricia LoRusso at the ongoing #AACR25. Many thanks for taking her precious time to introduce me to different KOL. G Curigliano MD PhD Toni Choueiri, MD

#AACR25 #ADC tour de force continues with talks by G Curigliano MD PhD, Sara Hurvitz Fred Hutch Cancer Center, and Hope Rugo on Challenges and Opportunities in the Development of Next Generation Antibody Drug Conjugates… and peptide drug conjugates!

Thank you. Fabulous session and honored to participate with my esteemed colleagues! Congrats and thanks to G Curigliano MD PhD for organizing and chairing our session. #AACR25 City of Hope

“Si cura meglio solo se si fa ricerca.” Da leggere tutto d’un fiato, ispirazione per chiunque voglia fare ricerca e medicina. G Curigliano MD PhD

G Curigliano MD PhD masterfully discusses various response "thresholds" across tumor types with TDXd. Why....If same target? How much it drives pathology of that cancer? #ESMOAmbassador #ESMOBreast25 ESMO - Eur. Oncology

Take home messages of a comprehensive overview on response and toxicity prediction biomarkers in ADC G Curigliano MD PhD ✅Few currently available biomarkers to guide selection ✅ A growing list of potential markers ✅ Need of Mechanisms to Discover and Validate biomarkers #ESMOBreast25

The #CuriglianoLab and alumni at #ESMOBreast25! From a group of Italian fellows to an international network of oncologists, researchers and friends - thanks to a bright vision. Grateful to be part of this family.

🇮🇹 🇪🇸 🇺🇸 axis United by friendship, passion and commitment to defeat breast cancer G Curigliano MD PhD Javier Cortes MD PhD #ESMOBreast25

🚨🥁Exciting Nature Medicine Publication Announcement 👉Hot off the press on this #ClinicalTrialsDay ! Thrilled to share our Nature Medicine paper: "Cancer treatment paradigms in the precision medicine era" 👉We propose 5 BOLD strategic recommendations to modernize cancer

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer in ESMO Open. 101 patients with solid tumors, ORR 77%, mDOR and mPFS 59 and 61 months, respectively. 88% of patients with TRAES, 26% of G3 or higher esmoopen.com/article/S2059-…

Very important paper!

🙏 Honored to speak at the #BIGNCTN in Chicago with DavidBraun & John Haanen. Grateful to share lung cancer vaccine insights & join the discussion on the potential of #CancerVaccines & #CellularTherapies with breast cancer leaders inc Nancy Lin, MD Seamus O’Reilly MD PhD & GiuseppeCurigliano

Final OS of CheckMate 9LA

Receiving the Yvonne “Top Voice” Award tonight was a honor. Receiving it from the hands of my first and lifelong mentor G Curigliano MD PhD — priceless. Thank you OncoDaily for this award!!!

EMBER-3 PROMs results reinforce the benefit of Imlunestrant as monotherapy or in combination with abemaciclib as an all-oral targeted therapy after progression on ET for HR+/HER2- ABC #ASCO25 OncoAlert #OncoAlert #BreastCancer

The #CuriglianoLab and alumni at #ASCO25